



October 11, 2023

Subject: Introducing HyQvia^{MD} in Canada

Dear Healthcare Professional,

Takeda Canada Inc. is pleased to announce the introduction of HyQvia^{MD}, a new Normal Immunoglobulin (Human) and Recombinant Human Hyaluronidase Solution for Subcutaneous Infusion Replacement Therapy for Immunodeficiencies. HyQvia is a dual vial size unit consisting of Normal immune globulin (Human) and Recombinant Human hyaluronidase (rHuPH20). Each vial of IG 10% is supplied with the required quantity of rHuPH20 and available in the following vial size formats: Normal Immunoglobulin (Human) 10% 2.5 g/25 mL, 5 g/50 mL, 10 g/100 mL, 20 g/200 mL, 30 g/300 mL and Recombinant Human Hyaluronidase 200 Units/1.25 mL, 400 Units/2.5 mL, 800 Units/5 mL, 1600 Units/10 mL and 2400 Units/15 mL Solution for Subcutaneous Infusion.

HyQvia is indicated as replacement therapy for primary humoral immunodeficiency (PI) and secondary humoral immunodeficiency (SI) in adult patients and will be available through Canadian Blood Services (CBS) in December 2023.

Obtain additional information on HyQvia^{MD} by:

consulting the HyQvia^{MD} Product Monograph that is available <https://www.takeda.com/en-ca/hyqviapm> or by contacting Takeda Medical Information at +1-800-268-2772 or medinfoCA@takeda.com.

Sincerely,

Ascher Essebag

Vice President, Rare Disease

22 Adelaide Street West, Suite 3800

Toronto, ON M5H 4E3, Canada

Telephone: +1.647.798.2200 or 1.866.397.4473

<https://www.takeda.com/en-ca>